The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix
Open accessAbstract
Purpose: To determine whether addition of gemcitabine to concurrent cisplatin chemoradiotherapy and as adjuvant chemotherapy with cisplatin improves progression-free survival (PFS) at 3 years compared with current standard of care in locally advanced cervical cancer. Patients and Methods: Eligible chemotherapy- and radiotherapy-naive patients with stage IIB to IVA disease and Karnofsky performance score ≥ 70 were randomly assigned to arm A (cisplatin 40 mg/m 2 and gemcitabine 125 mg/m 2 weekly for 6 weeks with concurrent external-beam radiotherapy [XRT] 50.4 Gy in 28 fractions, followed by brachytherapy [BCT] 30 to 35 Gy in 96 hours, and then two adjuvant 21-day cycles of cisplatin, 50 mg/m 2 on day 1, plus gemcitabine, 1,000 mg/m 2 on days 1 and 8) or to arm B (cisplatin and concurrent XRT followed by BCT only; dosing same as for arm A). Results: Between May 2002 and March 2004, 515 patients were enrolled (arm A, n = 259; arm B, n = 256). PFS at 3 years was significantly improved in arm A versus arm B (74.4% v 65.0%, respectively; P = .029), as were overall PFS (log-rank P = .0227; hazard ratio [HR], 0.68; 95% CI, 0.49 to 0.95), overall survival (log-rank P = .0224; HR, 0.68; 95% CI, 0.49 to 0.95), and time to progressive disease (log-rank P = .0012; HR, 0.54; 95% CI, 0.37 to 0.79). Grade 3 and 4 toxicities were more frequent in arm A than in arm B (86.5% v 46.3%, respectively; P < .001), including two deaths possibly related to treatment toxicity in arm A. Conclusion: Gemcitabine plus cisplatin chemoradiotherapy followed by BCT and adjuvant gemcitabine/cisplatin chemotherapy improved survival outcomes with increased but clinically manageable toxicity when compared with standard treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., Clarke-Pearson, D. L., & Insalaco, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401502 · Cited by 2,658
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Morris, M., Eifel, P. J., Lu, J., Grigsby, P. W., Levenback, C., Stevens, R. E., Rotman, M., Gershenson, D. M., & Mutch, D. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401501 · Cited by 2,299
Peters, W. A., Liu, P. Y., Barrett, R. J., Stock, R. J., Monk, B. J., Berek, J. S., Souhami, L., Grigsby, P., Gordon, W., & Alberts, D. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1606 · Cited by 2,284
Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, C. L., Walker, J. L., & Gersell, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401503 · Cited by 1,923
Whitney, C. W., Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, Jr., Clarke-Pearson, D. L., & Liao, S.-Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1339 · Cited by 1,524
Green, J. A., Kirwan, J. M., Tierney, J. F., Symonds, P., Fresco, L., Collingwood, M., & Williams, C. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05965-7 · Cited by 1,124
Eifel, P. J., Winter, K., Morris, M., Levenback, C., Grigsby, P. W., Cooper, J., Rotman, M., Gershenson, D., & Mutch, D. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.197 · Cited by 1,018
(2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4368 · Cited by 971
Perez, C. A., Grigsby, P. W., Castro-Vita, H., & Lockett, M. A. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00220-s · Cited by 441
Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix
Green, J. A., Kirwan, J. J., Tierney, J., Vale, C. L., Symonds, P. R., Fresco, L. L., Williams, C., & Collingwood, M. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002225.pub2 · Cited by 415
Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC) (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008285 · Cited by 275
Chen, S.-W., Liang, J., Yang, S.-N., Ko, H.-L., & Lin, F. (2003) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(02)00439-5 · Cited by 135
Chemoradiotherapy for cervical cancer
Rose, P. G. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00352-5 · Cited by 131
Radiosensitizers in cervical cancer. Cisplatin and beyond
Candelaria, M., Garcia-Arias, A., Cetina, L., & Dueñas‐González, A. (2006) · Radiation Oncology · doi:10.1186/1748-717x-1-15 · Cited by 110
Self-citationMonk, B. J., Tian, C., Rose, P. G., & Lanciano, R. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.12.027 · Cited by 98
Cited by
Cohen, P. A., Jhingran, A., Oaknin, A., & Denny, L. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32470-x · Cited by 2,412
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Clark, R., Cohn, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0001 · Cited by 1,054
Bermudez, A., Bhatla, N., & Leung, E. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2015.06.004 · Cited by 657
Gupta, S., Maheshwari, A., Parab, P., Mahantshetty, U., Hawaldar, R., Sastri (Chopra), S., Kerkar, R., Engineer, R., Tongaonkar, H., Ghosh, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.9985 · Cited by 459
Metadata
- Authors
- Dueñas-González, A., Zarbá, J. J., Patel, F., Alcedo, J. C., Beslija, S., Casanova, L., Pattaranutaporn, P., Hameed, S., Blair, J. M., Barraclough, H., & Orlando, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-01
- Volume
- 29
- Issue
- 13
- Pages
- 1678-1685
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104360894
- Cited by
- 484
- References
- 19
- FWCI
- 45.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.